Suraksha Diagnostic Q2 profit rises 69% to Rs 14.95 crore

Suraksha Diagnostic Limited reported consolidated profit of Rs 14.95 crore for the quarter ended 30 September 2026, up 69% year on year, while revenue from operations rose 26% to Rs 99.07 crore. Total expenses increased 21% to Rs 81.70 crore, slower than revenue growth, and profit before tax rose 57% to Rs 18.87 crore.

How did Suraksha Diagnostic perform in Q2 FY27?

Suraksha Diagnostic recorded Rs 99.07 crore of revenue from operations in the quarter ended 30 September 2026, compared with Rs 78.73 crore in the corresponding quarter of 2025. Other income rose to Rs 1.50 crore from Rs 85.14 lakh, taking total income to Rs 100.58 crore from Rs 79.58 crore.

Consolidated profit after tax rose to Rs 14.95 crore from Rs 8.83 crore, while profit before tax increased to Rs 18.87 crore from Rs 12.05 crore. Total comprehensive income was Rs 14.72 crore in the latest quarter, after an other comprehensive loss of Rs 22.70 lakh, compared with total comprehensive income of Rs 8.82 crore a year earlier.

Suraksha Diagnostic also improved from the immediately preceding quarter ended 30 June 2026, when revenue from operations was Rs 87.65 crore and profit after tax was Rs 12.85 crore. Profit before tax increased from Rs 16.53 crore in the June 2026 quarter to Rs 18.87 crore in the September 2026 quarter.

What drove Suraksha Diagnostic’s higher September-quarter profit?

Suraksha Diagnostic’s profit increase coincided with revenue rising faster than total expenses in the September 2026 quarter. Revenue from operations increased by Rs 20.34 crore year on year, while total expenses increased by Rs 14.17 crore, resulting in a Rs 6.83 crore increase in profit before tax.

On a calculated basis, profit after tax represented about 15.1% of revenue from operations in the quarter ended 30 September 2026, compared with about 11.2% a year earlier. Profit before tax represented about 19.0% of quarterly revenue, versus about 15.3% in the corresponding 2025 quarter; these are calculations from the reported consolidated figures, not management guidance.

Cost of materials consumed rose to Rs 11.25 crore from Rs 8.90 crore, while employee benefits expense increased to Rs 14.96 crore from Rs 13.39 crore. Other expenses rose to Rs 38.14 crore from Rs 32.12 crore, and depreciation and amortisation increased to Rs 12.61 crore from Rs 10.14 crore.

Finance costs were Rs 4.84 crore in the September 2026 quarter, compared with Rs 2.78 crore a year earlier. The statement reported an impairment write-back of Rs 9.23 lakh, against an impairment loss of Rs 20.46 lakh in the prior-year quarter, while total tax expense increased to Rs 3.92 crore from Rs 3.22 crore.

What do Suraksha Diagnostic’s first-half results show?

Suraksha Diagnostic reported revenue from operations of Rs 186.72 crore for the six months ended 30 September 2026, up from Rs 151.32 crore in the corresponding six months of 2025. Consolidated profit after tax increased to Rs 27.80 crore from Rs 18.00 crore, while profit before tax rose to Rs 35.40 crore from Rs 24.52 crore.

Total income for the first half was Rs 189.31 crore, compared with Rs 153.07 crore a year earlier, and total expenses rose to Rs 153.91 crore from Rs 128.56 crore. The difference between the 24% increase in total income and the 20% rise in expenses accompanied the 54% increase in first-half profit after tax.

Calculated first-half profit after tax margin was about 14.9% of revenue from operations, compared with about 11.9% in the previous corresponding period. The company reported basic and diluted earnings per equity share of Rs 5.38 for the six months ended 30 September 2026, and the equity shares have a face value of Rs 2 each.

Suraksha Diagnostic said its group primarily operates diagnostic centres providing pathology and radiology services, so it disclosed no separate reportable segments under Indian Accounting Standard 108, or Ind AS 108. The consolidated results include six subsidiaries, whose combined quarterly revenue before consolidation adjustments was Rs 5.26 crore and combined loss after tax was Rs 41.85 lakh, according to the auditors’ review report.

What changed in Suraksha Diagnostic’s balance sheet and cash flow?

Suraksha Diagnostic’s total assets increased to Rs 520.70 crore at 30 September 2026 from Rs 448.12 crore at 31 March 2026. Non-current assets rose to Rs 462.29 crore from Rs 385.54 crore, including property, plant and equipment of Rs 240.96 crore, up from Rs 193.58 crore at the March year-end.

Capital work-in-progress declined to Rs 16.70 crore from Rs 35.12 crore, while right-of-use assets increased to Rs 133.52 crore from Rs 116.06 crore. Total equity rose to Rs 275.04 crore from Rs 243.48 crore, and total liabilities increased to Rs 245.66 crore from Rs 204.64 crore.

Net cash generated from operating activities was Rs 58.79 crore for the six months ended 30 September 2026, compared with Rs 36.69 crore in the corresponding prior-year period. Investing activities used Rs 47.57 crore, including Rs 33.59 crore spent on property, plant and equipment, intangible assets, capital work-in-progress, capital advances and capital creditors.

Cash and cash equivalents stood at Rs 5.67 crore on 30 September 2026, compared with Rs 3.21 crore at 31 March 2026. Financing activities used Rs 8.77 crore during the first half, including Rs 13.81 crore of lease-liability payments and Rs 10.30 lakh of borrowing repayments, partly offset by Rs 5.75 crore of borrowing proceeds.

Conclusion

Suraksha Diagnostic’s September-quarter results showed profit increasing faster than revenue, with profit after tax up 69% to Rs 14.95 crore and revenue from operations up 26% to Rs 99.07 crore. The comparison with the prior-year quarter shows expenses rose 21%, while calculated net-profit margin increased by about 3.9 percentage points to about 15.1%.

The next results will show whether the balance-sheet change continues after property, plant and equipment increased by Rs 47.38 crore and capital work-in-progress declined by Rs 18.42 crore between 31 March and 30 September 2026. Suraksha Diagnostic did not disclose a numerical operating target, expansion timetable or separate segment outlook in the results approved on 10 November 2026.